JP Morgan initiated coverage on CeriBell with a new price target
$CBLL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
JP Morgan initiated coverage of CeriBell with a rating of Overweight and set a new price target of $32.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2025 | $32.00 | Buy | Ladenburg Thalmann |
| 11/5/2024 | $32.00 | Buy | BofA Securities |
| 11/5/2024 | $30.00 | Buy | Canaccord Genuity |
| 11/5/2024 | $32.00 | Overweight | JP Morgan |
| 11/5/2024 | $31.00 | Buy | TD Cowen |
| 11/5/2024 | Outperform | William Blair |
Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00
BofA Securities initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00
Canaccord Genuity initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00